Impact News +++ POET Wins Product Innovation Award and Individual Technology Innovation Award at China′s... (GlobeNewswire EN) +++ POET TECHNOLOGIES Aktie +3,09%

SHIONOGI Aktie

>SHIONOGI Aktienkurs

15.3 EUR -0.7% (Tradegate)

Ask: 15.3 EUR / 2000 Stück

Bid: 14.6 EUR / 500 Stück

Tagesumsatz: 10711 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

SHIONOGI Aktie über LYNX handeln

Intraday

1 Jahr

>SHIONOGI Performance

1 Woche: -1,9%

1 Monat: +3,3%

3 Monate: +12,3%

6 Monate: +8,0%

1 Jahr: +10,7%

laufendes Jahr: +0,6%

>SHIONOGI Aktie

Name:

SHIONOGI + CO. LTD

Land:

Japan

Sektor:

Gesundheit

ISIN/ Wkn:

JP3347200002 / 855648

Symbol/ Ticker:

SH0 (Frankfurt)

Kürzel:

FRA:SH0, ETR:SH0, SH0:GR

Index:

Nikkei225

Webseite:

http://www.shionogi.co.jp..

Profil:

Shionogi & Co., Ltd. is a prominent pharmaceutical..
>Volltext..

Marktkapitalisierung:

14040.5 Mio. EUR

Unternehmenswert:

12866.27 Mio. EUR

Umsatz:

2548.54 Mio. EUR

EBITDA:

1051.48 Mio. EUR

Nettogewinn:

995.74 Mio. EUR

Gewinn je Aktie:

1.17 EUR

Schulden:

132.3 Mio. EUR

Liquide Mittel:

1363.05 Mio. EUR

Operativer Cashflow:

1213.2 Mio. EUR

Bargeldquote:

1.77

Umsatzwachstum:

-3.67%

Gewinnwachstum:

1.9%

Dividende je Aktie:

0.38 EUR

Dividendenrendite:

2.25%

Dividendenschätzung:

2.25%

Div. Historie:

29.09.25 - 0.1880208€
28.03.25 - 0.1880208€

>weitere anzeigen...

Insiderhandel:

Suchwörter:

SHIONOGI

Letzte Datenerhebung:

20.01.26

>SHIONOGI Kennzahlen

Aktien/ Unternehmen:

Aktien: 850.98 Mio. St.

Frei handelbar: 78.43%

Leerverk. Aktien: -

Rückkaufquote: -

Mitarbeiter: 4955

Umsatz/Mitarb.: 0.51 Mio. EUR

Analysten:

Analystenrating: Neutral

Kursziel: -1.61%

Bewertung:

KGV: 13.06

KGV lG: 12.68

KUV: 5.45

KBV: 1.56

PEG-Ratio: 1.26

EV/EBITDA: 12.24

Rentabilität:

Bruttomarge: 84.92%

Gewinnmarge: 39.07%

Operative Marge: 36.5%

Managementeffizenz:

Gesamtkaprendite: 11.12%

Eigenkaprendite: 12.54%

>SHIONOGI Peer Group

Es sind 52 Aktien bekannt.

>SHIONOGI Chart & Kurs - Tradegate

>SHIONOGI News

20.01.26 - 10:36	Shionogi to Raise Stake in British HIV Drugs Firm ViiV (Nippon)
	Osaka, Jan. 20 (Jiji Press)--Japanese pharmaceutical company Shionogi & Co. said Tuesday that it will spend 2,125 million dollars to raise its stake in British HIV drugs company ViiV Healthcare Ltd. from 10 pct to 21.7 pct. ViiV will issue new shares to Shionogi for the additional investment. Procedures are expected to be completed by the end of March. ViiV will cancel the 11.7 pct stake ......

20.01.26 - 08:54	ViiV Healthcare: GSK, Pfizer und Shionogi ordnen Beteiligungen neu (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

20.01.26 - 08:24	Shionogi stockt Anteil an ViiV Healthcare auf – Pfizer steigt aus/n (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

20.01.26 - 01:24	Shionogi Invests $2.1 Billion to Raise ViiV Healthcare Stake (Bloomberg)
	Japanese pharmaceutical company Shionogi & Co. said it will invest $2.1 billion to raise its stake in ViiV Healthcare to 21.7%, making it an affiliate of the HIV drugmaker....

22.12.25 - 15:16	Tanabe Pharma America Announces Transfer of RADICAVA® Business to Shionogi (PR Newswire)
	U.S. and Canada transaction supports continued access to RADICAVA® for people living with ALS while enabling Tanabe Pharma America to focus on future growth and innovation JERSEY CITY, N.J., Dec. 22, 2025 /PRNewswire/ -- Tanabe Pharma America, Inc. (TPA), the wholly owned subsidiary of......

28.11.25 - 22:24	Nobel winner Sakaguchi, Japan′s Shionogi team on cancer treatment (Nikkei)
	Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...

30.10.25 - 18:48	Shionogi Announces Corporate Reorganization Following Japan Tobacco Pharma Merger (AFX)
	TOKYO (dpa-AFX) - Shionogi & Co., Ltd. Thursday announced it will implement a corporate reorganization and several personnel reassignments, effective December 1, 2025, in line with the upcoming ab......

28.10.25 - 03:42	Shionogi lifts profit outlook on HIV royalties and overseas growth (Japan Times)
	The company raised its full-year operating profit by 5.7% to ¥185 billion, beating analyst estimates....

27.10.25 - 11:36	Amended: Shionogi & Company H1 Net Profit Rises, But Revenue Slips; Revises Annual Outlook (AFX)
	TOKYO (dpa-AFX) - Shionogi & Company Limited (SGIOF, 4507.T), a Japanese pharmaceutical company, on Monday reported a rise in net profit for the first half, helped by an increase in finance income......

27.10.25 - 10:06	Shionogi Lifts Profit Outlook on HIV Royalties, Overseas Growth (Bloomberg)
	Shionogi & Co. lifted its full-year profit guidance as expected royalties from its HIV treatment surpass prior expectations....

27.10.25 - 08:48	Shionogi & Company H1 Net Profit Rises, But Revenue Slips; Revises Annual Outlook (AFX)
	TOKYO (dpa-AFX) - Shionogi & Company Limited (SGIOF, 4507.T), a Japanese pharmaceutical company, on Monday reported a rise in net profit for the first half, helped by an increase in finance income......

15.10.25 - 14:36

Gareth Morgan Named President of Qpex Biopharma, Inc. (Business Wire)

SAN DIEGO--(BUSINESS WIRE)--Qpex Biopharma, Inc., a Shionogi Group Company (hereafter “Qpex”), announced that Gareth Morgan, MS, MBA, most recently Senior Vice President and Global Head of Portfolio Management and AMR Policy at Shionogi Inc., has been appointed President of Qpex. Morgan succeeds Michael Dudley, Pharm.D., who has retired and stepped down from his role as President and CEO. Dr. Dudley will continue to serve as a strategic advisor to Qpex and Shionogi. Shionogi Inc., a U.S.-based subsidiary of Shionogi & Co., Ltd., acquired Qpex in 2023. The acquisition brought Qpex's expertise in antibiotic R&D along with its novel, internally discovered pipeline, including an investigational beta-lactamase inhibitor, to Shionogi, expanding the company's anti-infective pipeline and further augmenting its R&D capabilities and expertise. “I am honored to have led Qpex from its founding to becoming a Shionogi Group Company. Together we have expanded U.S.-based antibiotic R&D and are becoming true globa...

18.08.25 - 14:12	Shionogi Weighs Making Antibiotics in US Amid Rising Tariffs (Bloomberg)
	Shionogi & Co. is weighing producing its antibiotic Fetroja in the US as the pharma industry comes under pressure from President Donald Trump's tariffs....

08.08.25 - 18:12	Japan′s Shionogi plans US antibiotic plant with eye on Trump tariffs (Nikkei)
	Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...

28.07.25 - 10:39	Shionogi & Co. reports Q1 results (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

02.07.25 - 07:12	Forschungskooperation bringt Schweizer Biotechfirma BioVersys Millionen (Cash)
	Pharma - Die Schweizer Biotechfirma BioVersys hat eine Forschungs- und Lizenzvereinbarung mit dem japanischen Pharmaunternehmen Shionogi abgeschlossen....

02.07.25 - 07:03	Ad-hoc News: BioVersys AG (EQS)
	BIOVERSYS AND SHIONOGI ENTER INTO GLOBAL RESEARCH COLLABORATION FOR BROAD-SPECTRUM NON-TUBERCULOUS MYCOBACTERIA (NTM) CLINICAL CANDIDATE...

13.05.25 - 00:03	Shionogi & Co. GAAP EPS of ¥200.29, revenue of ¥438.27B (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

07.05.25 - 15:06

Shionogi to Acquire Torii Pharmaceutical (Nippon)

Tokyo, May 7 (Jiji Press)--Japanese drugmaker Shionogi & Co. said Wednesday that it will acquire Torii Pharmaceutical Co., a unit of Japan Tobacco Inc., for about 160 billion yen. Shionogi will aim to make Torii a fully owned subsidiary by conducting a tender offer and buying JT's stake in the firm. JT will fully withdraw from the pharmaceutical business, transferring all related operations ......

07.05.25 - 12:18	Japanese drugmaker Shionogi to acquire JT′s pharma units in $1.1bn deal (Nikkei)
	Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wer sich beständig ausschlußweise mit den Büchern beschäftigt, ist für das praktische Leben schon halb verloren. - Johann Gottfried Seume

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram